Clinical Trial Update: Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Abi/Pred plus ADT versus ADT alone in PSMA-positive, conventionally node-negative prostate cancer; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Abi/Pred
• Androgen deprivation therapy (ADT) (Androgen deprivation therapy)

Snippet

Sponsor: University of Nebraska | Conditions: Prostate Cancer | Phase 2 | Status: RECRUITING